-transparent.png){kind=logo}
Extended depletion of glutathione to approximately equal to 5% of control in the murine mammary carcinoma cell line 66 was achieved with a concentration of 0.05 mM buthionine sulfoximine. At 24 hours, there was no evidence for cellular toxicity from the BSO treatment per se; however, by 48 hours, there was inhibition of protein and DNA synthesis and cell growth and cell kinetic data was suggestive of both a G1 and a G2 block. Glutathione depletion to this extent (i.e., 0.13 mM vs. 2.24 mM in control) did not modify the aerobic radiation response for cells in the physiological states of proliferation, quiescence, or stimulated quiescent cells. This degree of cellular toxicity may well be cell-type dependent, but the results do suggest that caution is in order if one should attempt long-term GSH depletion in vivo.
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
May 1993,
Cancer research,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
July 1987,
British journal of cancer,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
June 1985,
Radiation research,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
February 2006,
Carcinogenesis,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
September 1995,
Research communications in molecular pathology and pharmacology,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
December 1989,
Urology,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
June 2012,
American journal of hypertension,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
May 1988,
Journal of neurochemistry,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
January 1986,
Investigational new drugs,
L A Dethlefsen, and
J E Biaglow, and
V M Peck, and
D N Ridinger
December 1988,
The American review of respiratory disease,
